Peptides are novel small molecules which contain about 2-50 amino acids and have critical role in human physiology, by acting as hormones, neurotransmitters, growth factors, antibacterial agents, amongst others.
Global Peptide Therapeutics Market & Clinical Trials Insight 2028 Report findings:
- Global Peptide Therapeutics Market Opportunity > USD 75 billion by 2028
- Global Peptide Therapeutics Clinical Trials Insight by Company, Indication & Phase
- Peptide Therapeutics in Clinical trials: > 800 Drugs
- Peptide Therapeutics Commercially Available In Market: > 200 Drugs
- Global Peptide Therapeutics Clinical Trials Insight By Peptide Type: Glucagon-like Peptides, Cyclic Peptides, Glycopeptides, Oligopeptides, Lipopeptides, Dipeptides, Opioid, Depsipeptides, Neuropeptides, Natriuretic, Bicyclic Peptides
Download Report:
https://www.pnspharma.com/reports/global-peptide-therapeutics-market-clinical-trials-insight-2028
Peptides are novel small molecules which contain about 2-50 amino acids and have critical role in human physiology, by acting as hormones, neurotransmitters, growth factors, antibacterial agents, amongst others. In addition to this, they have excellent diagnostic, preventive, and curative properties. The diverse functional capability of peptides is determined by the amino acid sequences and shape of the peptides. The wide range of applications of peptides has gained considerable attention from the pharmaceutical giants. Till date, more than 200 drugs have been approved for wide range of indications including cancer, cardiovascular diseases, rare diseases, and others.
Amid all categories of peptides, oligonucleotides have gained considerable interest as therapeutic drugs after the success of this family in the treatment of various severe genetic disorders, mainly in the past few years. For instance, Viltolarsen developed by NS Pharma is novel oligonucleotide which entered the market in 2020. It is prescribed to treat Duchenne’s muscular dystrophy (DMD) amenable to exon 53 skipping. In addition to this, about 20 oligonucleotide peptide drugs have also gained entry in to the market. Further, cyclic peptides have also gained momentum as they mbine several favorable properties such as good binding affinity, target selectivity and low toxicity that make them an attractive modality for the development of therapeutics. Over 40 cyclic peptide drugs are currently in clinical use.
The advancement in the field of science has led to further development of more enhanced bicycles peptide therapeutics. They can be optimized to have high affinity and exquisite selectivity to difficult-to-drug targets. Bicycles are being investigated in a number of ways and disease areas, including as cytotoxic targeting agents (Bicycle Toxin Conjugates, or BTCs) where a tumor-targeting Bicycle is linked to a toxin payload to form a drug conjugate. Further, Bicycles can also be joined with each other to form higher order structures such as tandems, trimers, and tetramers, allowing them to engage targets and target classes inaccessible to traditional small molecules or to engage multiple drug targets or cell types simultaneously. It is suggested that bicycles have the potential to become part of the next generation of therapeutics, combining specificity, potency, and attractive drug-like properties.
As per our report findings, the global peptide therapeutics market is expected to surpass US$ 75 Billion by 2028. Growing prevalence of chronic diseases, increased geriatric population, and growing investments in research and development by key players and government organizations are anticipated to drive the growth of market during the forecast period. Rapidly growing technological advancements in automation process and purity and rising awareness about growing application of peptides in the management of several diseases will also drive the growth of market.
North America and Europe is currently dominating the global market with more than 50% of the sales in this region. The rise in awareness levels about peptide therapeutics products, increasing demand for diagnostics in cancer and other diseases, and growing biotechnology industry are the factors contributing toward the dominance. Increasing research and development expenditure by the government is also estimated to help peptide therapeutics maintain dominance over the coming years. A well-established biopharmaceutical & pharmaceutical industry in this region is a major factor responsible for growth.
The report provides detailed review of the overall market landscape of peptide-based therapies, including information on their current phase of development (marketed, clinical, preclinical and discovery), type of peptide, route of administration, and key therapeutic area. The report also gives insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules. This report forecasts revenue growth at global and regional levels and provides an analysis of the latest trends and opportunities. The major companies mentioned in the report include Novartis, Pfizer, Roche, Lonza, Takeda Pharmaceutical, Teva Pharmaceutical, Ipsen, and others.
Contact:
Rajesh Arora
Senior Analyst
PNS Pharma